3-Month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: Results from an italian, open, multicenter trial

D. Fontana,M. Mari,A. Martinelli,C. Boccafoschi,Carlo Magno,M Turriziani,Ss Maymone,Sc Cunico,A. Zanollo,G. Montagna,M. Frongia,U. Jacobellis

3-Month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: Results from an italian, open, multicenter trial

2003

D. Fontana
M. Mari
A. Martinelli
C. Boccafoschi
Carlo Magno
M Turriziani
Ss Maymone
Sc Cunico
A. Zanollo
G. Montagna
M. Frongia
U. Jacobellis

Objectives: To determine the endocrine effects, efficacy and tolerability of the 3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot; ‘Zoladex’ is a trade mark of the

Keywords:

Urology
Goserelin Acetate
Internal medicine
Prostate-specific antigen
Endocrinology
Antiandrogen
Multicenter trial
Prostate cancer
Goserelin
Medicine
Depot
Tolerability
Prostatectomy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations